Search research articles
Contact Us
Filters
Showing results (91-100 of 119) with videos related to
Page
of 12
Sort By:
British Journal of Cancer
|
September 1, 1995
A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma
N M Bleehen, H V Newman, R P Rampling, et al.
European Urology
|
January 1, 1993
Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report
S J Harland, P A Cook, S D Fosså, et al.
British Journal of Cancer
|
February 5, 2004
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
D A Anthoney, M J McKean, J T Roberts, et al.
Journal of Clinical Pathology
|
June 1, 1974
Amino acid imbalance in cystinuria
A M Asatoor, P S Freedman, J R Gabriel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer
H Yosef, A Slater, C W Keen, et al.
British Journal of Urology
|
August 1, 1991
Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder
J T Roberts, S D Fossa, B Richards, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2001
Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy
K N Qureshi, T R Griffiths, M C Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer
K N Qureshi, T R Griffiths, M C Robinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2006
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer
J T Roberts, H von der Maase, L Sengeløv, et al.
British Journal of Cancer
|
March 20, 2003
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients
Y Vergouwe, E W Steyerberg, R de Wit, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 119) with videos related to
Sort By:
Page
of 12
British Journal of Cancer
|
September 1, 1995
A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma
N M Bleehen, H V Newman, R P Rampling, et al.
European Urology
|
January 1, 1993
Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report
S J Harland, P A Cook, S D Fosså, et al.
British Journal of Cancer
|
February 5, 2004
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
D A Anthoney, M J McKean, J T Roberts, et al.
Journal of Clinical Pathology
|
June 1, 1974
Amino acid imbalance in cystinuria
A M Asatoor, P S Freedman, J R Gabriel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer
H Yosef, A Slater, C W Keen, et al.
British Journal of Urology
|
August 1, 1991
Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder
J T Roberts, S D Fossa, B Richards, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2001
Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy
K N Qureshi, T R Griffiths, M C Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer
K N Qureshi, T R Griffiths, M C Robinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2006
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer
J T Roberts, H von der Maase, L Sengeløv, et al.
British Journal of Cancer
|
March 20, 2003
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients
Y Vergouwe, E W Steyerberg, R de Wit, et al.
Page
of 12